graft versus host disease Archive — Page 1 of 1

Stylized polygonal human profile facing a network of connected hexagons containing healthcare symbols, including a cross, heart monitor, eye, syringe, pills, lungs, thermometer, stethoscope, laboratory flask, and hospital symbol, on a purple-to-blue digital background.
April 7, 2022

Computer eyeballs graft-vs-host disease

A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.

By Paul Govern
Portrait of Madan Jagasia wearing glasses, a dark suit, white shirt, and patterned tie against a brown background.
June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC’s Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

By Tom Wilemon
Large outdoor crowd gathered on tiered steps, with many people standing, watching, and taking photos in bright sunlight.
February 21, 2019

Skin diseases study uses crowdsourcing to gather data

In 1906, English statistician Francis Galton happened to visit a livestock fair where fairgoers were invited to guess the dressed weight of an ox scheduled for imminent slaughter. Some 800 attendees took part and afterwards Galton got hold of the contest data.

By Paul Govern